Intramuscular Islet Autograft

Small molecule

Intramuscular Islet Autograft is one of 5 small molecule programs targeting Pancreatectomy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PancreatectomyActive, not recruiting

PancreatectomyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Pancreatectomy

#DrugCompanyPhaseTrials

Indocin

LLife Extension Foundation Inc.

Signifor

1 3

Botox

RRevance Therapeutics, Inc.

Phase 2

1 4

Intramuscular Islet Autograft

UUniversity Hospital, Lille

Preclinical

1 5

Etamsylate

FFirst Affiliated Hospital of Zhejiang University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatectomy1 trial

Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy

Active, not recruiting·UUniversity Hospital, Lille·Phase 1/2·NCT02872571·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intramuscular Islet Autograft. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intramuscular Islet Autograft compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intramuscular Islet Autograft. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Lille company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity Hospital, Lille

Intramuscular Islet Autograft

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatectomy1 trial

References

Drug Info

Quick Facts

Related News